Who
Phillip G. Febbo
Chief Scientific & Med Officer
Company insider
Files Form 4 as: Chief Scientific & Med Officer, Veracyte; SVP Chief Medical Officer, Illumina; Director, Varian Medical Systems; Chief Medical Officer, Genomic Health.
In numbers
- Trades disclosed
- 101
- Buys
- 0
- Sells
- 16
- Bought
- $0
- Sold
- $5.3M
- Companies
- 4
- Companies where not an officer
- 1
- First trade
- 15 Aug 2015
- Last trade
- 4 Sep 2026
- Last filed
- 4 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 4 Sep 2026filed 4 Sep 2026 | VCYT VeracyteDiagnostics & Labs | SEC FORM 4 Sold | $446K10,405 at $42.89 | filing |
| 4 Sep 2026filed 4 Sep 2026 | VCYT VeracyteDiagnostics & Labs | SEC FORM 4 Sold | $118K2,705 at $43.66 | filing |
| 4 Sep 2026filed 4 Sep 2026 | VCYT VeracyteDiagnostics & Labs | SEC FORM 4 Sold | $446K10,405 at $42.89 | filing |
| 4 Sep 2026filed 4 Sep 2026 | VCYT VeracyteDiagnostics & Labs | SEC FORM 4 Sold | $118K2,705 at $43.66 | filing |
| 2 Sep 2026filed 4 Sep 2026 | VCYT VeracyteDiagnostics & Labs | SEC FORM 4 Code F | $163K3,639 at $44.88 | filing |
| 2 Sep 2026filed 4 Sep 2026 | VCYT VeracyteDiagnostics & Labs | SEC FORM 4 Code F | $163K3,639 at $44.88 | filing |
| 2 Jun 2026filed 4 Jun 2026 | VCYT VeracyteDiagnostics & Labs | SEC FORM 4 Code F | $178K3,730 at $47.80 | filing |
| 2 Jun 2026filed 4 Jun 2026 | VCYT VeracyteDiagnostics & Labs | SEC FORM 4 Code F | $178K3,730 at $47.80 | filing |
| 6 Mar 2026filed 10 Mar 2026 | VCYT VeracyteDiagnostics & Labs | SEC FORM 4 Code A | —29,603 at $0.00 | filing |
| 6 Mar 2026filed 10 Mar 2026 | VCYT VeracyteDiagnostics & Labs | SEC FORM 4 Code A | —6,578 at $0.00 | filing |
| 6 Mar 2026filed 10 Mar 2026 | VCYT VeracyteDiagnostics & Labs | SEC FORM 4 Code A | —29,603 at $0.00 | filing |
| 6 Mar 2026filed 10 Mar 2026 | VCYT VeracyteDiagnostics & Labs | SEC FORM 4 Code A | —6,578 at $0.00 | filing |
| 2 Mar 2026filed 4 Mar 2026 | VCYT VeracyteDiagnostics & Labs | SEC FORM 4 Code F | $217K6,035 at $36.01 | filing |
| 2 Mar 2026filed 4 Mar 2026 | VCYT VeracyteDiagnostics & Labs | SEC FORM 4 Sold | $485K13,425 at $36.16 | filing |
| 2 Mar 2026filed 4 Mar 2026 | VCYT VeracyteDiagnostics & Labs | SEC FORM 4 Code F | $217K6,035 at $36.01 | filing |
| 2 Mar 2026filed 4 Mar 2026 | VCYT VeracyteDiagnostics & Labs | SEC FORM 4 Sold | $485K13,425 at $36.16 | filing |
| 26 Feb 2026filed 2 Mar 2026 | VCYT VeracyteDiagnostics & Labs | SEC FORM 4 Code A | —71,806 at $0.00 | filing |
| 26 Feb 2026filed 2 Mar 2026 | VCYT VeracyteDiagnostics & Labs | SEC FORM 4 Code F | $949K24,486 at $38.75 | filing |
| 26 Feb 2026filed 2 Mar 2026 | VCYT VeracyteDiagnostics & Labs | SEC FORM 4 Code A | —71,806 at $0.00 | filing |
| 26 Feb 2026filed 2 Mar 2026 | VCYT VeracyteDiagnostics & Labs | SEC FORM 4 Code F | $949K24,486 at $38.75 | filing |
News
Veracyte's Decipher Can Help Men Detect Prostate CancerVCYT · finanzen.ch · 23 Oct 2026Phase III Trial Shows Veracyte's Decipher Prostate Test Can Predict Benefit from Adding Abiraterone to Treatment in Very High-Risk Prostate CancerVCYT · manilatimes.net · 23 Oct 2026
0 headlines in the last 90 days name Phillip G. Febbo; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.